Piper Sandler Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $15.00

Keros Therapeutics (NASDAQ:KROS) had its price target cut by analysts at Piper Sandler from $40.00 to $15.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s price objective would suggest a potential upside of 35.53% from the company’s current price.

KROS has been the subject of several other reports. TD Cowen downgraded shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Wells Fargo & Company upped their target price on Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Oppenheimer reduced their price target on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $52.56.

Keros Therapeutics Price Performance

NASDAQ:KROS traded up $0.55 during trading hours on Friday, hitting $11.07. The company’s stock had a trading volume of 1,876,504 shares, compared to its average volume of 2,501,869. Keros Therapeutics has a twelve month low of $9.77 and a twelve month high of $73.00. The stock has a fifty day simple moving average of $37.51 and a 200-day simple moving average of $47.36. The company has a market capitalization of $448.36 million, a P/E ratio of -2.13 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.33) EPS. On average, equities analysts predict that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of the company. KBC Group NV increased its stake in Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of Keros Therapeutics in the 3rd quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Keros Therapeutics in the 2nd quarter valued at about $128,000. Finally, LMR Partners LLP bought a new position in Keros Therapeutics in the 3rd quarter valued at about $213,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.